Huttig Bldg Products (HBP) 5.42 $HBP Helix BioPharma

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 8:02 AM

Huttig Bldg Products (HBP) 5.42 $HBP

Helix BioPharma Corp. Appoints Evolution Life Science Partners as Advisors
Marketwired - Thu Jun 02, 7:00AM CDT
AURORA, ON--(Marketwired - Jun 2, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Evolution Life Science Partners to act as advisors to the Company. Activities the Company may pursue could include, but are not limited to, partnering or other collaboration agreements. The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations.
HBP: 5.42 (+0.09), HBP.TO: 1.89 (unch)

Huttig Adopts Rights Plan to Protect Net Operating Loss Carryforwards
Marketwire Canada - Thu May 19, 3:30PM CDT
ST. LOUIS, MO --(Marketwired - May 19, 2016) - Huttig Building Products, Inc. ("Huttig"

(NASDAQ: HBP) today announced that its Board of Directors has adopted a rights plan as a measure to protect the Company's existing net operating loss carryforwards ("NOLs"

and preserve the Company's ability to use its NOLs to offset future taxable income, without limitation. As of March 31, 2016, the Company had Federal NOL carryforwards of approximately $55 million. The Company intends to seek stockholder approval of the rights plan at its 2017 Annual Meeting of Stockholders.
HBP: 5.42 (+0.09)

First Patient Dosed in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Wed May 11, 6:30AM CDT
AURORA, ON--(Marketwired - May 11, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient was dosed in the Phase II component of study LDOS002.
HBP: 5.42 (+0.09), HBP.TO: 1.89 (unch)

Helix BioPharma Corp. Subsidiary, Helix Polska Sp zo.o., Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development
Marketwire Canada - Mon May 09, 6:30AM CDT
AURORA, ON--(Marketwired - May 9, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its wholly owned subsidiary, Helix Polska Sp. z o.o. qualifies for a grant of approximately PLN12.5mil from the Polish National Centre for Research and Development to develop V-DOS47 in breast cancer. The acceptance of the grant is subject to review and approval of the final terms and conditions by Helix's management and Board of Directors and may be subject to conditions imposed by the granting authority and corporate or other approvals.
HBP: 5.42 (+0.09), HBP.TO: 1.89 (unch)

Huttig posts 1Q profit
Automated Insights - Mon May 02, 3:57PM CDT
ST LOUIS (AP) _ Huttig Building Products Inc. (HBP) on Monday reported profit of $1.4 million in its first quarter.
HBP: 5.42 (+0.09)

Huttig Building Products, Inc. Announces First Quarter 2016 Results
Marketwired - Mon May 02, 3:30PM CDT
First Quarter 2016 Highlights:
HBP: 5.42 (+0.09)

Helix BioPharma Corp. Closes CAD4.7 Million Private Placement Financing
Marketwired - Fri Apr 29, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD4.7 million.
HBP: 5.42 (+0.09), HBP.TO: 1.89 (unch)

First Patient Enrolled in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 28, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient has been enrolled in the Phase II component of study LDOS002.
HBP: 5.42 (+0.09), HBP.TO: 1.89 (unch)

Trial Steering Committee Recommends Initiation of Phase II L-DOS47 Study in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 21, 4:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recommendation by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study.
HBP: 5.42 (+0.09), HBP.TO: 1.89 (unch)

Helix BioPharma Corp. Announces Important Additions to Its Leadership Team
Marketwire Canada - Wed Apr 20, 6:30PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Dr. Patrick Frankham to Chief Operating Officer and the promotion of Mr. Steve Demas to the position of Chief Medical Officer. Dr. Frankham and Mr. Demas will both report directly to Dr. Sven Rohmann, Helix's newly appointed Chief Executive Officer.
HBP: 5.42 (+0.09), HBP.TO: 1.89 (unch)

Huttig Building Products Schedules First Quarter 2016 Earnings Call
Marketwired - Mon Apr 18, 3:30PM CDT
Huttig Building Products (NASDAQ: HBP), one of the nation's largest wholesale distributors of millwork and specialty building products used principally in new residential construction and home improvement, plans to report its first quarter 2016 financial results before the market opens on Tuesday, May 3, 2016. A conference call with management to review the results and current market conditions is scheduled on the same day at 10:00 am Central Time. The call will be hosted by Jon Vrabely, President and CEO and Oscar Martinez, Vice President and CFO.
HBP: 5.42 (+0.09)

Helix Biopharma Corp. Announces the Receipt of Subscription Agreements Totalling CAD4.7 Million for Private Placement Financing
Marketwire Canada - Fri Apr 15, 6:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for units for aggregate gross proceeds of approximately CAD4.7 million.
HBP: 5.42 (+0.09), HBP.TO: 1.89 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AT&T Surges with Major Revenue Boost and Fiber Expansion

AT&T's stirring up the pot with a third-quarter blowout that even the cleverest of market watchers had to tip their hats to. Barely anyone had five years ago pegged the sleepy telecom to launch past some of the juggernauts in service revenue growth. But here we are, folks—the company clocking a solid $32.3 billion in revenue, trundling in at a thick 5.3% from the...

AHN Opens Clinic for Severe Postpartum Tear Care

A Game Changer for Postpartum Recovery When it comes to childbirth, you think you've heard it all, but here's a twist—Allegheny Health Network (AHN) just swung the doors open on a clinic laser-focused on a very raw deal: third- and fourth-degree perineal lacerations. We're diving into new territory where one network sees the gap and jumps into action, calling in the...

Aduna's New APIs: Combatting Fraud with Big Players

Aduna's Transformative Move Every so often, a partnership pops up and smashes through the fog in the tech world like a diamond in the rough. For Aduna, hooking up with titans like AT&T, T-Mobile, and Verizon ain't just another Tuesday. They've got sights set on delivering three potent fraud-fighting APIs that'll hit the market come Q4. And for any business manager who's...

PG&E Delivers $26M Climate Credit to Small Biz

California's Big Move for Small Businesses In a world where every dollar counts, small businesses across Northern and Central California are getting a helping hand. Pacific Gas and Electric Company (PG&E) is stepping up with a tidy little climate credit thanks to the state's Cap-and-Invest Program. Eligible businesses are automatically set to receive a $36.18 credit off...

Tax Strategy Crucial: Sidnell & Webster of Lufkin Weigh In

Breaking Down Tax Prep vs. Planning Ever wonder why some folks never break a sweat come tax season, while others scramble like their hair's on fire? It all boils down to understanding two very different animals: tax preparation and tax planning. CPA veterans Yvette Sidnell and Jennifer Webster over in Lufkin, Texas, have laid it out crystal clear in their article with...

Tech Shapes Car Buying Yet Dealers Still Rule

Car-Buying Matrix: Digital Tools and Physical Showrooms Let me tell ya, even as we're up to our eyeballs in tech, seems like folks still can't wean off the good ol' car dealership. Over 80% of car buyers toss a mix of online and in-person sleuthing into the deal, yet nine out of ten won't take the plunge till they've shaken a dealer's hand. Why's that? Trust? Habit? Who...

Industrial Defender Boosts OT Cybersecurity Capabilities

OT Cybersecurity Takes a Step Forward So today, it’s all about this new roll-out by Industrial Defender. Just another tool shedding light in those dim corners of network security for critical infrastructure operators. Honestly, these folks have been at this for quite some time—talking 20 years uphill and still pushing. From Anomalies to Action Their latest magic?...

Goodyear Preps for Q3 2026 Earnings Report, Call

Gearing Up for Goodyear's Latest Financials Here we go, folks—Goodyear Tire & Rubber Company is ready to roll out their third quarter's financial results for 2026. Come November 4, after the market goes to sleep, the big wigs at Goodyear will toss out the numbers. We’ll all get the chance to dig into the figures that they’ll slap on their investor website. Then,...

Conscious Spark Debuts Alphimiya® To Break Revenue Barriers

Unlocking Enterprise Potential With Neuroscience Pioneering a fresh avenue in business strategy, Conscious Spark LLC unveils its latest innovation, Alphimiya®, a framework that rewires the executive brain for greater financial scalability. We're talking about a dive into the autonomic nervous system here—why settle for spreadsheets when you can tweak brainwaves for...

IBM Backs Leena AI: Shaping Enterprise Automation

IBM's Strategic Bet on Enterprise Automation Diving into the blazing 2026 market, IBM Ventures has thrown its weight behind Leena AI, an enterprise agentic AI firm that's out to shake things up. You see, the name of the game isn't just flashy AI chatbots anymore. Companies like Leena AI are setting their sights on the back-office grunt work—the lifeblood operations in...